Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Durvalumab + Vactosertib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Durvalumab + Vactosertib | Phase Ib/II | Actionable | In a Phase Ia/II trial, combination treatment with Vactosertib (TEW 7197) and Imfinzi (durvalumab) demonstrated safety and antitumor activity in CD274 (PD-L1)-positive non-small cell lung cancer patients, and led to an objective response rate of 30.8% and 40.0% in patients with CD274 (PD-L1) expression >= 1% and >=25% respectively (Journal for ImmunoTherapy of Cancer 2020;8; NCT03732274). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result | Full reference... |